Citation:Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, et al 2011

From Cancer Guidelines Wiki

Citation


Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011 Jun;6(6):1039-49 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21512408.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, et al 2011When is IHC required for subtyping of NSCLC and what is the optimal IHC panel?Associate Professor Wendy Coopercompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:When is IHC required for subtyping of NSCLC and what is the optimal IHC panel?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:When is IHC required for subtyping of NSCLC and what is the optimal IHC panel?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. When is IHC required for subtyping of NSCLC and what is the optimal IHC panel?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Pelosi_G,_Rossi_G,_Bianchi_F,_Maisonneuve_P,_Galetta_D,_Sonzogni_A,_et_al_2011&oldid=107037"